- Institut Pasteur
- Support us
The chikungunya virus, transmitted by Aedes mosquitoes, causes severe joint pain in affected patients. The disease is mainly endemic in South Asia and Africa. In 2005, a major chikungunya epidemic struck the islands in the Indian Ocean, particularly Reunion Island, with hundreds of thousands of reported cases. In 2007, the disease arrived in Europe for the first time, and the mosquito vector Aedes albopictus is now established on the continent. The first indigenous cases in France were reported in 2010. Existing treatment options are purely symptomatic.
The chikungunya virus is an arbovirus (a virus transmitted by arthropods) that is spread by the female mosquitoes of the Aedes genus, primarily from the two species Aedes aegypti and Aedes albopictus. These two mosquitoes can also transmit other arboviruses including dengue and yellow fever.
In the Makonde language, chikungunya means “walking bent over”, an allusion to the stooped posture of chikungunya patients crippled by painful joints.
After an incubation period of 2 to 10 days, the chikungunya virus causes severe, often debilitating joint pain in infected patients, mainly in small joints such as the wrists, fingers, ankles, and feet, but sometimes in the knees and occasionally in the hips or shoulders. Those affected also frequently suffer from headaches, fever, severe muscle pain, a rash on the torso and limbs, swelling in one or more cervical lymph nodes, and conjunctivitis.
Bleeding gums and nosebleeds have often been described in connection with the disease, mainly in Asia.
Although complicated forms of chikungunya had only rarely been observed, during the 2005 epidemic on Reunion Island severe neurological forms were reported, with cases of meningoencephalitis and damage to peripheral nerves. These complications mainly affected elderly patients, those with a weakened immune system, or newborn babies who had been infected in utero by their mothers.
The clinical symptoms of chikungunya usually disappear relatively quickly – patients tend to recover from the fever and rashes associated with the disease within a few days, but joint problems can persist for several weeks. Infection by the chikungunya virus does not seem to have been the direct cause of the small number of fatalities recorded during epidemics.
Joint pain can persist in subacute or chronic form for several months or even years, particularly in older patients. In a retrospective South African study, 10% of patients were still affected 3 to 5 years after acute infection by the chikungunya virus.
The first epidemic caused by the chikungunya virus was recorded in Tanzania in 1952. Since then, infection by the chikungunya virus has continued to develop in endemic and epidemic form on the African and Asian continents, particularly in India since 2006 (with around 2 million confirmed and suspected cases) and in the Indian Ocean region. In 2007, chikungunya was also recorded in Europe for the first time, with several hundred cases in Italy in September of that year. In 2010, the first two indigenous cases of chikungunya were recorded in France.
There is a real possibility that the chikungunya virus might spread in the warmer regions of Europe, where the Aedes albopictus mosquito vector has become widespread. In September 2007, an epidemic outbreak occurred in the Ravenna region of Italy, affecting some three hundred people. It is believed to have been introduced by a traveler returning from India. The first two indigenous cases of chikungunya in France were detected in 2010. The risk of dengue and chikungunya becoming endemic in southern Europe therefore needs to be taken seriously. This has led to chikungunya being added to the notifiable diseases list, and surveillance measures have been stepped up since January 2006.
The transmission area for the chikungunya virus encompasses the whole of Sub-Saharan Africa and South-East Asia. In Africa, the virus is spread via a jungle cycle involving primates and sylvatic mosquitoes ( Aedes luteocephalus , Aedes furcifer , and Aedes taylori). In Asia, wher e the virus was introduced more recently, it circulates in a mainly u rban cycle, involving the Aedes aegypti and Aedes albopictus mosquitoes.
Since it was first described in Tanzania, the chikungunya virus has regularly caused small-scale cyclical epidemic outbreaks in rural areas, mainly in southern and eastern Africa, from Uganda to South Africa, and in Central Africa. The most recent major epidemic on the African continent was in 2007 in Gabon, with 5,000 suspected cases. The chikungunya virus is occasionally seen in West Africa, particularly Senegal. It is considered as endemic in rural areas of Africa, where it is likely responsible for several undiagnosed cases.
Epidemic outbreaks have also been observed in India, Sri Lanka, South-East Asia (Thailand, Myanmar, Vietnam, Laos, Cambodia, Indonesia, and more recently Malaysia), and the Philippines. Some isolated cases were reported in Singapore in 2009. A major epidemic struck India in January 2006 and has continued to spread, with some two million suspected cases reported to date. The higher frequency of epidemics in Asia can be explained by the prevalence of mosquito vectors that are more anthropophilic (preferring humans) in these areas.
In the Indian Ocean region, no cases of chikungunya were reported before the beginning of 2005, when a first epidemic, thought to have emerged in East Africa, hit the Comoros. The virus was most likely spread by the Aedes aegypti mosquito, which is widespread in this archipelago.
In March 2005, the epidemic rapidly spread throughout Reunion Island from the north west, with a major outbreak between late April and early June. The virus continued to spread during the austral winter months. On this island, the virus was mainly transmitted by the Aedes albopictus mosquito, which is highly versatile – it can colonize both urban and sylvatic environments and use both artificial and natural breeding grounds. A total of around 270,000 people are thought to have been infected, out of a total population of 750,000. At the same time, from the end of March 2005, the Seychelles, Mauritius, and Mayotte were also affected by the chikungunya virus epidemic, with cases increasing from January 2006. The virus also circulated widely in Madagascar. Two imported cases from Madagascar were identified in French Guiana in March 2006, highlighting the risk of an outbreak of the virus in the French Caribbean. In spring 2010, chikungunya struck again on Reunion Island, with around twenty confirmed cases.
Medical treatment for chikungunya is purely symptomatic and is based on painkillers and anti-inflammatory drugs. But these treatments are unable to prevent chronic progression of the disease. Corticosteroid treatment may be necessary for patients who develop subacute or chronic symptoms.
The prevention of chikungunya involves individual and collective efforts to improve vector control. Individuals can limit their exposure to the mosquito vector by wearing long clothes, applying insect repellant and treating clothes with insecticides, and using mosquito nets. Larger-scale vector control involves pre-emptive spraying with insecticides and removing potential breeding grounds, particularly around living areas (flower pots and other containers, used tires, bulky waste, etc.).
The Institut Pasteur’s response to the threat of chikungunya back in 2005 is a prime example of the swift, effective action of its scientists. At the peak of the epidemic, in 2006, the Institut Pasteur in Paris launched a vast research program on the chikungunya virus involving a dozen teams coordinated by Felix Rey, Head of the Virology Department. They developed diagnostic tests in record time, traced the evolutionary history of the virus, sequenced the genomes of several viral strains, and identified the origins of the epidemic. The scientists also developed an animal model of the disease, designed a vaccine candidate, and identified the human cells targeted by the virus and the genes capable of controlling infection. Other research pinpointed the virulence factors of the virus and shed light on the transmission methods used by Aedes albopictus.
Around ten teams are still focusing their research on chikungunya. The Flavivirus-Host Molecular Interactions Unit, directed by Philippe Desprès, is particularly looking at the mechanisms used by the chikungunya virus to escape the host cell’s antiviral defense mechanisms. The unit is involved in the KerARBO project that was funded by the French National Research Agency in 2012 and is coordinated by the Development Research Institute (IRD) in Montpellier. The aim of this project is to understand the replication mechanisms of the chikungunya virus on the skin, where it is actually inoculated into humans by mosquitoes, and to develop innovative antiviral strategies. In cooperation with the Institut Pasteur’s Laboratory for Urgent Response to Biological Threats, the unit has also developed a novel technological platform for research into the prevalence of chikungunya in populations in endemic regions. This process has been patented. The Viral Genomics and Vaccination Unit (led by Frédéric Tangy) in collaboration with the Flavivirus-Host Molecular Interactions Unit has developed a vaccine candidate against Chikungunya based on the use of pediatric measles vaccine. A phase I clinical trials on this candidate vaccine measles-chikungunya is planned soon by the austrian biotech company THEMIS Biosciences, based in Vienna.
Recently, several Institut Pasteur teams, coordinated by Antoine Gessain, have joined forces in the DEVA Transversal Research Program, which has led to the development of a molecular diagnostic tool for chikungunya, dengue, and West Nile virus at the Institut Pasteur’s Paris campus. The tool uses a DNA microarray to analyze serum or blood samples and diagnose acute viral infection. The microarray can also characterize the genome of the virus or viruses in the infected test sample.
Copyright - Institut Pasteur
Caption – Chikungunya virus particles on the surface of an infected cell (a human fibroblast).
> Arboviruses and Insect Vectors Laboratory
led by Anna-Bella Failloux
> Oncogenic Virus Epidemiology and Pathophysiology Unit
led by Antoine Gessain
> Viral Genomics and Vaccination Unit
led by Frédéric Tangy
> Dendritic Cell Immunobiology Unit
led by Matthew Albert
> Flavivirus-Host Molecular Interactions Unit
led by Philippe Desprès
> Structural Virology Unit
led by Felix Rey
> Virus and Immunity Unit
led by Olivier Schwartz
> Microorganisms and Host Barriers Group
led by Marc Lecuit
> Viral Populations and Pathogenesis Group
led by Marco Vignuzzi
> Genotyping of Pathogens and Public Health Platform
co-led by Sylvain Brisse and Valérie Caro
209-211 rue de Vaugirard
0 890 710 811 (0,15 €/mn)